Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 11
1966 30
1967 33
1968 30
1969 60
1970 32
1971 27
1972 33
1973 37
1974 39
1975 51
1976 83
1977 96
1978 68
1979 69
1980 67
1981 82
1982 107
1983 90
1984 95
1985 88
1986 114
1987 128
1988 139
1989 114
1990 168
1991 183
1992 201
1993 187
1994 238
1995 259
1996 252
1997 310
1998 268
1999 357
2000 335
2001 294
2002 285
2003 336
2004 378
2005 422
2006 458
2007 540
2008 491
2009 500
2010 556
2011 686
2012 656
2013 629
2014 645
2015 674
2016 560
2017 536
2018 447
2019 483
2020 453
2021 544
2022 526
2023 433
2024 511
2025 571
2026 201

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,989 results

Results by year

Filters applied: . Clear all
Page 1
Noninferiority of One HPV Vaccine Dose to Two Doses.
Kreimer AR, Porras C, Liu D, Hildesheim A, Carvajal LJ, Ocampo R, Romero B, Gail MH, Cortes B, Sierra MS, Coronado K, Sampson J, Coto C, Dagnall CL, Mora D, Kemp TJ, Zuniga M, Pinto LA, Barrientos G, Schussler J, Estrada Y, Montero C, Avila C, Ruggieri D, Cyr JT, Chanock S, Lowy DR, Schiller JT, Herrero R. Kreimer AR, et al. N Engl J Med. 2025 Dec 18;393(24):2421-2433. doi: 10.1056/NEJMoa2506765. Epub 2025 Dec 3. N Engl J Med. 2025. PMID: 41337735 Clinical Trial.
A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma.
Blass E, Keskin DB, Tu CR, Forman C, Vanasse A, Sax HE, Shim B, Chea V, Kim N, Carulli I, Southard J, Lyu H, Lu W, Rickles-Young M, Afeyan AB, Olive O, Mehndiratta A, Greenslade H, Shetty K, Baginska J, Gomez Diaz I, Nau A, Pfaff KL, Gans A, Ranasinghe S, Buchbinder EI, Sussman TA, Insco ML, Yoon CH, Rodig SJ, Shukla SA, Li S, Aster JC, Braun DA, Cibulskis C, Hacohen N, Neuberg DS, Giobbie-Hurder A, Livak KJ, Fritsch EF, Oliveira G, Simon JM, Wu CJ, Ott PA. Blass E, et al. Cell. 2025 Sep 18;188(19):5125-5141.e27. doi: 10.1016/j.cell.2025.06.019. Epub 2025 Jul 10. Cell. 2025. PMID: 40645179 Clinical Trial.
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Cuadripani S, Deraedt Q, Dezutter N, Gerard C, Fissette L, Xavier S, David MP, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 study group. Ison MG, et al. Lancet Respir Med. 2025 Jun;13(6):517-529. doi: 10.1016/S2213-2600(25)00048-7. Epub 2025 Apr 14. Lancet Respir Med. 2025. PMID: 40245915 Clinical Trial.
High-Dose Influenza Vaccine to Reduce Hospitalizations.
Pardo-Seco J, Rodríguez-Tenreiro-Sánchez C, Giné-Vázquez I, Mallah N, Mirás-Carballal S, Piñeiro-Sotelo M, Cribeiro-González M, Conde-Pájaro M, González-Pérez JM, Rivero-Calle I, Bello X, Razzini JL, Dacosta-Urbieta A, Salas A, Harris RC, Loiacono MM, van Aalst R, Farré JM, Dufournet M, Johansen ND, Modin D, Biering-Sørensen T, Durán-Parrondo C, Martinón-Torres F; GALFLU Trial Team. Pardo-Seco J, et al. N Engl J Med. 2025 Dec 11;393(23):2303-2312. doi: 10.1056/NEJMoa2509834. Epub 2025 Aug 30. N Engl J Med. 2025. PMID: 40888694 Clinical Trial.
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.
Willis JR, Prabhakaran M, Muthui M, Naidoo A, Sincomb T, Wu W, Cottrell CA, Landais E, deCamp AC, Keshavarzi NR, Kalyuzhniy O, Lee JH, Murungi LM, Ogonda WA, Yates NL, Corcoran MM, Phulera S, Musando J, Tsai A, Lemire G, Sein Y, Muteti M, Alamuri P, Bohl JA, Holman D, Himansu S, Leav B, Reuter C, Lin LA, Ding B, He C, Straus WL, MacPhee KJ, Regadas I, Nyabundi DV, Chirchir R, Anzala O, Kimotho JN, Kibet C, Greene K, Gao H, Beatman E, Benson K, Laddy D, Brown DM, Bronson R, Jean-Baptiste J, Gajjala S, Rikhtegaran-Tehrani Z, Benner A, Ramaswami M, Lu D, Alavi N, Amirzehni S, Kubitz M, Tingle R, Georgeson E, Phelps N, Adachi Y, Liguori A, Flynn C, McKenney K, Zhou X, Owuor DC, Owuor SA, Kim SY, Duff M, Kim JY, Gibson G, Baboo S, Diedrich J, Schiffner T, Shields M, Matsoso M, Santos J, Syvertsen K, Kennedy A, Schroeter M, Vekemans J, Yates JR 3rd, Paulson JC, Hyrien O, McDermott AB, Maenetje P, Nyombayire J, Karita E, Ingabire R, Edward V, Muturi-Kioi V, Maenza J, Shapiro AE, McElrath MJ, Edupuganti S, Taylor BS, Diemert D, Ozorowski G, Koup RA, Montefiori D, Ward AB, Karlsson Hedestam GB, Tomaras G, Hunt DJ, Muema D, Sok D, Laufer DS, Andrews SF, Nduati EW, Schief WR. Willis JR, et al. Science. 2025 Jul 31;389(6759):eadr8382. doi: 10.1126/science.adr8382. Epub 2025 Jul 31. Science. 2025. PMID: 40373112 Free PMC article. Clinical Trial.
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
Daneshmand S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, Bögemann M, Simone G, Pieczonka CM, Casco NC, Zainfeld D, Spiegelhalder P, Xylinas E, Cahn D, Lotan Y, Murray KS, Kawahara T, Stromberg K, Martin J, Shukla A, Cutie CJ, Bertzos K, Hampras S, Sweiti H, Necchi A; SunRISe-1 Study. Daneshmand S, et al. J Clin Oncol. 2025 Nov 20;43(33):3578-3588. doi: 10.1200/JCO-25-01651. Epub 2025 Jul 30. J Clin Oncol. 2025. PMID: 40737582 Free PMC article. Clinical Trial.
Precise targeting of HIV broadly neutralizing antibody precursors in humans.
Caniels TG, Prabhakaran M, Ozorowski G, MacPhee KJ, Wu W, van der Straten K, Agrawal S, Derking R, Reiss EIMM, Millard K, Turroja M, Desrosiers A, Bethony J, Malkin E, Liesdek MH, van der Veen A, Klouwens M, Snitselaar JL, Bouhuijs JH, Bronson R, Jean-Baptiste J, Gajjala S, Rikhtegaran Tehrani Z, Benner A, Ramaswami M, Duff MO, Liu YW, Sato AH, Kim JY, Baken IJL, Mendes Silva C, Bijl TPL, van Rijswijk J, Burger JA, Cupo A, Yasmeen A, Phulera S, Lee WH, Randall KN Jr, Zhang S, Corcoran MM, Regadas I, Sullivan AC, Brown DM, Bohl JA, Greene KM, Gao H, Yates NL, Sawant S, Prins JM, Kootstra NA, Kaminsky SM, Barin B, Rahaman F, Meller M, Philiponis V, Laufer DS, Lombardo A, Mwoga L, Shotorbani S, Holman D, Koup RA, Klasse PJ, Karlsson Hedestam GB, Tomaras GD, van Gils MJ, Montefiori DC, McDermott AB, Hyrien O, Moore JP, Wilson IA, Ward AB, Diemert DJ, de Bree GJ, Andrews SF, Caskey M, Sanders RW. Caniels TG, et al. Science. 2025 Jul 31;389(6759):eadv5572. doi: 10.1126/science.adv5572. Epub 2025 Jul 31. Science. 2025. PMID: 40373114 Free PMC article. Clinical Trial.
BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.
Schmidt AC, Fairlie L, Hellström E, Luabeya Kany Kany A, Middelkoop K, Naidoo K, Nair G, Gela A, Nemes E, Scriba TJ, Cinar A, Frahm N, Mogg R, Kaufman D, Dunne MW, Hatherill M; BCG REVAX Study Team. Schmidt AC, et al. N Engl J Med. 2025 May 8;392(18):1789-1800. doi: 10.1056/NEJMoa2412381. N Engl J Med. 2025. PMID: 40334156 Free PMC article. Clinical Trial.
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD. Shore ND, et al. Nat Med. 2025 Aug;31(8):2806-2814. doi: 10.1038/s41591-025-03738-z. Epub 2025 May 31. Nat Med. 2025. PMID: 40450141 Free PMC article. Clinical Trial.
RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults.
Lassen MCH, Johansen ND, Christensen SH, Aliabadi N, Skaarup KG, Modin D, Claggett BL, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Lindholm MG, Jensen AMR, Dons M, Bernholm KF, Davidovski FS, Duus LS, Ottosen CI, Nielsen AB, Borchsenius JH, Espersen C, Köse G, Fussing FH, Køber L, Solomon SD, Jensen JUS, Martel CJ, Gessner BD, Schwarz C, Gonzalez E, Skovdal M, Moulton LH, Zhang P, Begier E, Biering-Sørensen T. Lassen MCH, et al. N Engl J Med. 2026 Jan 8;394(2):138-151. doi: 10.1056/NEJMoa2509810. Epub 2025 Aug 30. N Engl J Med. 2026. PMID: 40888695 Clinical Trial.
15,989 results
You have reached the last available page of results. Please see the User Guide for more information.